{"disease":{"id":"malignant-melanoma-stage-iii","name":"malignant melanoma stage iii"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04056247","title":"Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"OncoHost Ltd.","has_results":false},{"nct_id":"NCT05334069","title":"Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT04314401","title":"National Cancer Institute \"Cancer Moonshot Biobank\"","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1600,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03819296","title":"Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06075524","title":"Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04949113","title":"Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":423,"lead_sponsor_name":"The Netherlands Cancer Institute","has_results":false},{"nct_id":"NCT07259304","title":"Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT02419495","title":"Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":221,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04067960","title":"Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":197,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04079166","title":"SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":173,"lead_sponsor_name":"Scancell Ltd","has_results":false},{"nct_id":"NCT07405086","title":"Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT02304458","title":"Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06794775","title":"SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":128,"lead_sponsor_name":"Hildur Helgadottir","has_results":false},{"nct_id":"NCT06708455","title":"Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":65,"lead_sponsor_name":"Rapa Therapeutics LLC","has_results":false},{"nct_id":"NCT03707574","title":"Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study","phase":"","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01480154","title":"Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":62,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02595866","title":"Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05039801","title":"IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02910700","title":"Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":52,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04771520","title":"Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06265285","title":"Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04133948","title":"Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"The Netherlands Cancer Institute","has_results":false},{"nct_id":"NCT01638533","title":"Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01303341","title":"Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":35,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04940299","title":"Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":35,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03493230","title":"Detection of Plasmatic Cell-free BRAF and NRAS Mutations : a New Tool for Monitoring Patients With Metastatic Malignant Melanoma Treated With Targeted Therapies or Immunotherapy ( MALT )","phase":"NA","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT03590054","title":"Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Rahul Aggarwal","has_results":false},{"nct_id":"NCT01973322","title":"Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized \"Proof-of-principle\" Phase II Study","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","has_results":false},{"nct_id":"NCT01902173","title":"Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05098210","title":"Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT02097225","title":"Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":22,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03541148","title":"Evaluation of Oncoxin-Viusid® in Cutaneous Melanoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Catalysis SL","has_results":false},{"nct_id":"NCT04902040","title":"Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":19,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT02650986","title":"Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":15,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT03229278","title":"Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":true},{"nct_id":"NCT03112668","title":"Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners","phase":"NA","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":false},{"nct_id":"NCT04514484","title":"Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04577729","title":"The IRMI-FMT Trial","phase":"NA","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Medical University of Graz","has_results":false},{"nct_id":"NCT04221438","title":"Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":true},{"nct_id":"NCT03326258","title":"Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06626256","title":"STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"City of Hope Medical Center","has_results":false}],"total":42},"guidelines":[],"source":"Drug Landscape verified database"}